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Abstract The Hunter Outcome Survey (HOS), an internation-
al, long-term observational registry of patients with Hunter
syndrome, was used to develop a simple mnemonic screening
tool (HUNTER) to aid in the diagnosis of Hunter syndrome.
Data regarding the prediagnosis prevalence of ten specific
signs and symptoms present in individual patients enrolled in
the HOS were used to develop the HUNTER mnemonic
screening tool. A total score of 6 or greater using a weighting
scheme in which certain manifestations were assigned a weight
of 2 (facial dysmorphism, nasal obstruction or rhinorrhea,
enlarged tongue, enlarged liver, enlarged spleen, joint stiffness)
and others assigned a weight of 1 (hernia, hearing impairment,
enlarged tonsils, airway obstruction or sleep apnea) correctly
identified 95% of patients who had no family history of Hunter
syndrome or who were not diagnosed prenatally. No associa-
tion between age at diagnosis and HUNTER score was found.
Conclusion: The HUNTER mnemonic appears to be a useful
screening tool. Further validation in the clinical setting will be
necessary to confirm its utility.
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Introduction
Hunter syndrome (mucopolysaccharidosis type II or MPS
II) is an X-linked metabolic disorder caused by a deficiency
in the lysosomal enzyme iduronate-2-sulfatase (I2S) [1, 12].
I2S catalyzes a step in the degradation of dermatan sulfate
and heparan sulfate [12], and in affected patients, these
enzyme substrates accumulate in cells and tissues and con-
tribute to the multiorgan pathologies associated with Hunter
syndrome. It has been estimated that the incidence is about 1
in 162,000 live male births [9]. Hunter syndrome patients
usually appear normal at birth with clinical signs and symp-
toms emerging between the ages of 2 and 4 years [8, 12].
The presenting signs typically include coarse facial features;
respiratory obstruction caused by enlarged tongue, tonsils,
and adenoids; joint stiffness and skeletal abnormalities; and
enlarged liver and spleen [15–17]. Two phenotypes are
recognized—severe and attenuated. The severe phenotype
is characterized by progressive central nervous system in-
volvement that results in severe cognitive impairment and
developmental regression, with death typically occurring
in the second decade of life [7, 12, 17]. Patients with
the attenuated phenotype do not experience cognitive
impairment but may still demonstrate all of the somatic
signs and symptoms of the disease [8, 12, 16]. These
patients may survive into adulthood, although premature
mortality occurs [7].
Diagnosis of Hunter syndrome can be challenging as
signs and symptoms of Hunter syndrome are not specific
to the disease, and not all clinical features will be present in
the same order or equally rapidly in each patient. Diagnosis
may therefore be delayed, especially in patients without a
known family history of Hunter syndrome. Enzyme replace-
ment therapy (ERT) with recombinant human I2S is avail-
able for the treatment of Hunter syndrome [10, 11]. In
addition to ERT, there is a hope that Hunter syndrome
may be responsive to bone marrow transplantation in the
future [5]. Therefore, although a rare disease, pediatricians
and other primary care physicians have an obligation to be
aware of the signs and symptoms of Hunter syndrome and
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methods and tools to effectively establish a diagnosis. Mne-
monics are commonly employed in clinical medicine as
screening tools or to guide clinical management [2, 13],
and here, we describe the development of a simple mne-
monic screening tool that may aid pediatric specialists and
primary care physicians in the recognition and diagnosis of
Hunter syndrome.
Patients and methods
Hunter outcome survey
Hunter Outcome Survey (HOS) is an international, long-
term observational registry designed to increase the knowl-
edge of the natural history of Hunter syndrome and to
evaluate the safety and effectiveness of long-term ERT with
idursulfase (Elaprase®, Shire Human Genetic Therapies,
Inc. (Shire HGT), Lexington, MA, USA) [15]. All partici-
pating centers receive approval from their local institutional
review board or ethics committee before enrolling any
patients into HOS. HOS is controlled by physicians and is
overseen by national, regional, and international advisory
boards comprising physicians experienced in the manage-
ment and treatment of Hunter syndrome patients. Any pa-
tient with a biochemically or genetically confirmed
diagnosis of Hunter syndrome is eligible to enroll in HOS
independent of whether receiving treatment or not. All
patients and/or their guardians provide informed written
consent prior to participation in HOS.
The HOS database consists of data collected from med-
ical examinations conducted during the usual medical care
of the patients. The signs, symptoms, and other clinical
information (e.g., medical history, laboratory values, etc.)
surveyed are described in detail by Wraith and colleagues
[15] and cover all the major organ and system involvement
that occurs in Hunter syndrome. Shire HGT maintains the
database and provides statistical support to HOS physicians
and advisory boards. For the purposes of this study, the
investigators were given permission, by the global executive
committee of the HOS participating investigators, to query
the database regarding the prevalence of specific signs and
symptoms present in individual patients. The preliminary
assessment was based on the HOS database as of January
10, 2008, and the final assessment was based on the April
16, 2009 data extract.
Hunter mnemonic
The goal of the present study was to develop a sensitive
screening tool to aid in the diagnosis of Hunter syndrome
using medical history data collected in HOS. Table 1
presents the HUNTER mnemonic, which was based on the
key clinical features observed in patients with Hunter syn-
drome. The January 2008 data extract of the HOS database
was queried for the prevalence of the signs and symptoms
before diagnosis within individual patients as shown in
Table 2. A random sample of 25 patients in HOS with
available information and who did not have a prenatal
diagnosis was used to characterize the utility of a uniform
weighting (Table 2, weighting 1) of these ten signs and
symptoms to specifically identify patients with Hunter syn-
drome. A second weighting scheme was also evaluated
(Table 2, weighting 2) using a second random sample of
25 patients in HOS with available information who were not
included in the first sample and who did not have a prenatal
diagnosis or family history of Hunter syndrome. With this
scheme, signs and symptoms unlikely to be observed in a
non-affected child were given a score of 2. These signs and
symptoms included dysmorphic facial features, nasal ob-
struction, enlarged tongue, enlarged liver, enlarged spleen,
and joint stiffness. The remaining signs and symptoms were
given a score of 1. A total score between 0 and 16 was
assigned to each patient. After this preliminary evaluation of
the weighting schemes, weighting 2 was again evaluated
using the April 2009 extract of the HOS database, which
included 237 patients with available data who did not have a
prenatal diagnosis or a family history of Hunter syndrome
and who were not included in the two random samples of 25
patients used to assess the two weighting schemes.
Table 1 The HUNTER mne-
monic screening instrument for
identifying patients with Hunter
syndrome
Mnemonic Key clinical feature
H Hernia
Hearing
Hernia
Hearing loss or impairment, hearing aids, chronic or acute otitis
U Unusual faces Dysmorphic facial features
N Nasal obstruction Nasal obstruction, rhinorrhea
T Tongue and tonsils Enlarged tongue, enlarged tonsils
E Enlarged liver and spleen Hepatomegaly, splenomegaly
R Respiration
Range of motion
Airway obstruction, sleep apnea
Joint stiffness
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Analysis
No formal statistical analysis of the weighting schemes was
performed. The investigators relied on their clinical experi-
ence to determine if the results appeared to be specific
enough to correctly identify patients with Hunter syndrome.
Results
As of April 16, 2009, a total of 541 prospective patients (i.e.,
alive at HOS entry) were enrolled in HOS. The mean patient
age at their most recent examination as entered into HOS was
12.3 years (median 10.3 years, 10th–90th percentile 3.7–
23.4 years). These patients had been enrolled in HOS for a
mean of 10.4 months. The age at onset of signs and symptoms
and the age at diagnosis are summarized in Table 3.
Figure 1 illustrates the results of the preliminary testing
of the utility of uniform weighting (weighting 1) of the ten
signs and symptoms presented in Table 2 as well as the
second weighting scheme (weighting 2) using a second
random sample. No threshold HUNTER score was found
that could identify a Hunter patient without yielding too
many false negative results. For example, a score of 1 failed
to identify 12 % of the patients with Hunter syndrome and a
score of 2 failed to identify 20 % of the patients. The failure
of uniform weighting to identify Hunter syndrome patients
was likely due in part to the fact that patients with a family
history of Hunter syndrome were included in the test sample
of 25 randomly selected patients. Because a family history
of Hunter syndrome may result in diagnosis before the
emergence of many signs and symptoms, this test sample
included many patients with low scores. In addition, many
of the signs and symptoms are common in children without
Hunter syndrome, e.g., otitis and rhinorrhea.
Weighting scheme 2 (Table 2) was developed to give
greater weight to those signs and symptoms that are more
likely to be specifically associated with Hunter syndrome.
Preliminary testing with 25 randomly selected patients from
HOS who did not have a family history of Hunter syndrome
suggested that a HUNTER score of 6 or 7 would correctly
identify more than 95 % of patients with Hunter syndrome.
Weighting 2 was further evaluated by using the 237
patients in HOS who had complete information regarding
the prevalence of signs and symptoms and who had no pre-
natal diagnosis and no family history of Hunter syndrome. A
score of 6 or greater correctly identified 95 % of this popula-
tion as having Hunter syndrome (Fig. 2). No association
between age of diagnosis and HUNTER score at diagnosis
was observed (Fig. 3). The median (10th–90th percentile)
HUNTER score for patients <2, 2 to 4, and >4 years old at
diagnosis was 12 (7–16), 13 (8–16), and 13 (7–16),
respectively.
Table 2 Signs and symptoms used in the development of the HUNT-
ER score screening tool
Signs or symptoms Weighting 1 Weighting 2
Hernia 1 1
Hearing loss, use of a hearing aid, acute
or chronic otitis
1 1
Dysmorphic facial features 1 2
Nasal obstruction or rhinorrhea 1 2
Enlarged tongue 1 2
Enlarged tonsils 1 1
Hepatomegaly 1 2
Splenomegaly 1 2
Airway obstruction or sleep apnea 1 1
Joint stiffness 1 2
Maximum score for a patient 10 16
Table 3 Age at onset of signs and symptoms and diagnosis of Hunter syndrome
Number Mean (years) Median (years) 10th to 90th percentile
Age at onset of symptoms 405 2.0 1.5 0.2–4.0
Age at diagnosis 479 4.0 3.5 1.2–7.1
Delay between onset of symptoms and diagnosis 399 1.9 1.3 0–4.4
Based on prospective patients (i.e., alive at HOS entry) from the April 16, 2009 data extract
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Fig. 1 Preliminary testing of weighting schemes for the HUNTER
score. The black bars represent weighting 1, and the gray bars repre-
sent weighting 2. The maximum score for weighting 1 is 10, and the
maximum score for weighting 2 is 16. N=25 randomly selected
patients from HOS. Based on two random samples of patients from
the January 10, 2008 data extract. HOS Hunter Outcome Survey
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Discussion
This simple mnemonic screening tool correctly identified
patients as having Hunter syndrome with 95 % accuracy at a
HUNTER score of 6 or above. This score appears to be
unlikely to be attained by a person without Hunter syndrome
or other MPS disorders.
Mnemonics are frequently used in clinical practice as
screening tools or to guide clinical management, for ex-
ample, mnemonic or scoring systems have been employed
to screen newborns for Down syndrome [6], to identify
infants in need of resuscitation [4], and to describe heart
sounds [14].
The early diagnosis of Hunter syndrome remains a chal-
lenge [3]. A newborn screening test is not yet available, and
the low awareness of rare, genetic diseases hinders the
recognition and diagnosis of this syndrome. Most pediatri-
cians will never encounter a child with this syndrome during
their entire careers. The recognition and diagnosis of Hunter
syndrome is often delayed because its complex and diverse
signs and symptoms are not specific to Hunter syndrome [8],
making a simple tool to help narrow the differential diagnosis
is an asset in pediatric and primary care settings.
The goal of the present study was to develop a simple,
sensitive, and unified screening tool for identifying Hunter
syndrome. The first iteration in which the ten signs and
symptoms were given equal weight was not sufficiently
sensitive and failed to yield a reliable threshold score that
would identify Hunter syndrome without producing a large
number of false negatives (and presumably false positives).
The inclusion of patients with a family history of Hunter
syndrome may have contributed to the failure of uniform
weighting to correctly identify patients with Hunter syn-
drome because these patients may have had earlier diagno-
ses before the emergence of many signs and symptoms of
Hunter syndrome than patients without a family history. The
final iteration in which the Hunter syndrome-specific signs
and symptoms were weighted 2 points (Table 2) appeared to
correctly identify 95 % of Hunter patients in the study
cohort with a HUNTER score of 6 or higher. Additionally,
it seems unlikely that patients without Hunter syndrome or
other MPS disorders would be likely to meet or exceed this
threshold HUNTER score. It is important to note that ex-
ceeding this threshold is only suggestive of Hunter syn-
drome and biochemical and/or genetic confirmation is still
necessary to confirm the presence of this disease and other
forms of MPS.
We acknowledge that this tool requires validation in a
clinical setting to assess the tool’s sensitivity, specificity,
positive and negative predictive values, and patient variabil-
ity across all types of pediatric patients. This study repre-
sents the first step in the development of tool based on
hundreds of observations of children with Hunter syndrome,
which would otherwise be impossible to develop without
such a registry, given the rarity of this disorder. The tool at
present is likely to generate false positive but may also help
in the identification of other children with rare inherited
disease, which will still be of great value. We hope this
paper will serve as a first step toward a more refined tool
with high predictive value.
Conclusions
The HUNTER mnemonic had a sensitivity of over 95 % to
detect Hunter syndrome at a HUNTER score of 6 or greater
and, given the overlap of clinical features, may also help in
the identification of other MPSs. Validation of this tool in
the clinical setting will be required to determine the
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Fig. 2 HUNTER evaluation with patients in HOS with complete
information. N=237 patients enrolled in HOS with complete informa-
tion. Based on the April 16, 2009 data extract and excluding patients
with missing information, prenatal diagnosis, or family history of
Hunter. HOS Hunter Outcome Survey
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Fig. 3 The association between HUNTER score and age at diagnosis.
N=237 patients in HOS with complete information. Based on the April
16, 2009 data extract and excluding patients with missing information
or with prenatal diagnosis or family history of Hunter. HOS Hunter
Outcome Survey
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sensitivity, specificity, as well as positive and negative pre-
dictive value of this tool, and to confirm its utility as a
screen for Hunter syndrome in routine clinical practice.
The approach described herein illustrates the utility of dis-
ease registries in the development of tools that may assist
physicians in the diagnosis and management of rare, genetic
disorders. As newborn screening for Hunter syndrome is
presently unavailable, it is hoped that this simple mnemonic
and associated scoring system will prove useful for pedia-
tricians or other primary care clinicians when faced with a
patient with Hunter syndrome or other MPS disease.
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